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in alleviating chronic fatigue syndrome symptoms, with overall evidence narrow and inconsistent across
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Abstract 6 
Objective: To review the evidence for the role of dietary modifications in alleviating chronic fatigue 7 
syndrome symptoms. 8 
Methods: A systematic literature review was guided by PRISMA and conducted using Scopus, 9 
CINAHL Plus, Web of Science and PsycINFO scientific databases (1994-2016) to identify relevant 10 
studies. Twenty-two studies met the inclusion criteria, the quality of each paper was assessed and 11 
data extracted into a standardised tabular format.  12 
Results: Positive outcomes were highlighted in some included studies for polyphenol intakes in 13 
animal studies, D-ribose supplementation in humans and aspects of symptom alleviation for one of 14 
three polynutrient supplement studies. Omega three fatty acid blood levels and supplementation 15 
with an omega three fatty acid supplement also displayed positive outcomes in relation to chronic 16 
fatigue syndrome symptom alleviation.  17 
Conclusions: Limited dietary modifications were found useful in alleviating chronic fatigue 18 
syndrome symptoms, with overall evidence narrow and inconsistent across studies.  19 
Implications for Public Health: Due to the individual and community impairment chronic fatigue 20 
syndrome imparts on the population, it is vital that awareness and further focused research on this 21 
topic is undertaken to clarify and consolidate recommendations and ensure accurate, useful 22 
distribution of information at a population level.  23 
 24 
Abstract Word Count: 193 25 
 26 
Introduction  27 
Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), recently redefined by the 28 
Institute of Medicine as Systemic Exertion Intolerance Disease (SEID)
1
, is a chronic multisystemic 29 
condition which severely impacts daily life, impairing a persons ability to perform every day tasks 30 
due to overwhelming fatigue, in turn affecting quality of life.
1-6
 For the purpose of this review the 31 
term CFS will be used. Symptoms characteristic to CFS include immobilising fatigue, sleep 32 
disturbance, headaches, difficulty concentrating as well as muscular pain.
2, 5
 The aetiology behind 33 
CFS is unknown, with new diagnostic criteria
1
 and name (SEID) aimed at improving diagnostic 34 
time as well as consolidating the focus of new research to address the cause of CFS.
1, 3, 4, 6
 35 
Furthermore, recent findings of an objective characteristic chemical signature for CFS are hoping to 36 
 2 
also prove useful in eliminating diagnostic uncertainty going forward, highlighting CFS as a pattern 37 
of hypometabolic response to environmental stress.
7
 CFS community prevalence is estimated to be 38 
0.2% to 0.7% in the United States and United Kingdom,
6, 8, 9
 although valid epidemiological data is 39 
limited.
3, 10, 11
 Not only is the individual and their quality of life impacted but the community itself 40 
is as well. The economic impact of CFS within the limited Australian data available is estimated at 41 
$13471 annually per case for the year 2000 for individual medical costs and time lost in 42 
productivity.
8
 The overall annual direct and indirect economic costs being estimated at $525 43 
million.
8
 More recent United States data suggests an annual direct and indirect cost estimate of $17-44 
24 billion dollars.
12
 Research into effective treatment of CFS symptoms is vital, particularly that 45 
addressing treatment using dietary modification rather than pharmacological measures.  46 
Previous reviews on CFS have not concentrated solely on the effectiveness of dietary modification, 47 
as, to the knowledge of the authors, data specific to this research question is limited.
5, 13-15
 48 
Complementary and alternative medicine therapies were the focus of previously conducted CFS 49 
reviews, with some studies briefly discussing dietary modification amongst a vast range of other 50 
alternative and pharmacological therapies.
5, 13-15
 This review intends to highlight research in this 51 
field with specific focus on dietary modifications alone. By examining the current literature 52 
surrounding the topic, this review will identify effective dietary modifications for use. Due to the 53 
narrow extent of studies available,
5, 13-15
 literature reviewed in this study is comprised of data on 54 
dietary modification by food, supplementation or dietary outcome assessment and its impact on 55 
alleviating the symptoms of persons with CFS across a range of study designs. Inclusion across a 56 
range of study designs effectively highlights the current state of evidence for this topic. This study 57 
aims to review data on dietary modification in food or supplement form or dietary outcome 58 
assessment in relation to CFS. The research hypothesis stands on the alternative hypothesis that 59 
dietary modifications alone are useful in alleviating the symptoms of CFS. 60 
 61 
Methods: 62 
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement 63 
protocol was used to inform the methods used in this systematic review
16
 (Supplementary File 1). 64 
Data Collection 65 
The scientific databases Scopus, CINAHL Plus, Web of Science and PsychINFO were searched in 66 
May 2014 (1994-2014). A date limit was applied due to limited awareness and work surrounding 67 
CFS, with the first case definition only developed after 1988.
10
 An updated database search was 68 
performed for the period of June 2014 to August 2016, limited only by date. The search terms, 69 
developed from the initially selected key words, medical subject headings (MeSH) terms and 70 
synonyms, were used within Boolean search strategies across the for-mentioned databases. The 71 
 3 
search terms included “chronic fatigue syndrome”, “CFS”, “myalgic encephalomyelitis”, “diet” and 72 
“supplementation”.  73 
To systematically gather all available evidence, animal as well as human observational and 74 
experimental study designs were included if they met inclusion criteria parameters. The broad range 75 
of study designs were chosen to be included as the extent of research surrounding this topic is 76 
narrow.  77 
 78 
Study Selection 79 
For inclusion in this review, studies needed to provide data on dietary outcomes assessment or 80 
modification in food or supplement form in relation to CFS and its symptoms, or a model of CFS 81 
and its accompanying symptoms. For those studies considering supplement use, the Therapeutic 82 
Goods Regulations 1990
17
 was consulted, with a number of designated active ingredients excluded 83 
from inclusion in this review. This ensured the review held its focus on dietary modification rather 84 
than pharmacological measures. Studies were required to be published studies in the English 85 
language, and were excluded if published more than twenty two years ago. Only original studies 86 
were included with editorials and letters excluded. Studies were selected ensuring that they met the 87 
inclusion criteria, had relevant findings and showed some level of validity through quality 88 
assessment methods.
18-20
 89 
Relevant studies were selected from the pool of studies returned by the searches performed across 90 
each database by initially screening the title and abstract. For preliminary screening, if the title and 91 
abstract did not provide sufficient information or the abstract was unavailable the full study was 92 
screened. The subsequent full text studies were then reviewed to ensure they met the inclusion 93 
criteria, were primary studies and were not reviewing disproved treatment strategies such as 94 
homeopathy.
21
 95 
 96 
Data Extraction  97 
Upon gathering data from the included primary studies, a standardised table was developed in order 98 
to extract appropriate information (see Supplementary File 2, accessible online). The data extracted 99 
from each study pertained to study design, level of evidence
18
 and use of a control group. It also 100 
included the intervention details (range of exposure and length to follow up), study population 101 
characteristic (sample size, gender, loss to follow up or non-response), duration, outcome measures, 102 
results, confounders, external validity (applicability and generalisablity) as well as an overall 103 
quality rating
20
 which was reached through in depth assessment of study validity.  104 
 105 
Quality and Risk of Bias Assessment 106 
 4 
For the included primary studies the level of evidence of each included study was graded according 107 
to the National Health and Medical Research Council
18
 A quality rating was assigned according to 108 
the Academy of Nutrition and Dietetics American Dietetic Association
20
 quality rating checklist, 109 
allowing for an assessment of risk of bias within each included study and fostering systematic and 110 
objective quality rating assignment. The checklist addresses relevance, applicability, validity and 111 
bias,
20
 These aspects of quality and bias are found within the summary table. Ethics approval of all 112 
included studies was also considered.  113 
 114 
Study Outcomes 115 
The summary table was used to systematically extract data from each study included in the review 116 
in order to make clear comparisons and provide a brief overview of all studies. Results are reported 117 
according to prominent data themes which emerged from the review.  118 
 119 
Results 120 
Study Retrieval  121 
Across the identified databases 435 potential primary research papers were identified (see 122 
Supplementary File 3 for expanded search details, viewable online). Of these, 22 primary research 123 
papers were included in the systematic review.  124 
 125 
Animal studies and polyphenols  126 
Three animal studies were included examining the effect of differing polyphenols and their impact 127 
on induced CFS symptoms in mice or rats.
22-24
 These polyphenols included astragalus 128 
membranaceus flavonoids (AMF), epigallocatechin gallate (EGCG) and naringin. 129 
The effect of AMF oral administration in rats highlighted statistically significant increases in 130 
endurance through forced swimming compared to rats not administered with AMF (p<0.05) in the 131 
chronically fatigued groups.
22
 Spleen cell proliferation was statistically significantly increased with 132 
AMF supplementation (p<0.05) as well as abnormal cytokine production levels being regulated 133 
(p<0.05) in chronically fatigued groups.
22
 134 
Daily EGCG oral administration highlighted a significant increase in endurance capacity during 135 
forced swimming and decreased post swim fatigue levels compared to the chronic fatigue rat group 136 
at 28 days (p= <0.05). Greater endurance and decreased post fatigue levels were displayed with the 137 
administration of 100 mg/kg compared to 50 mg/kg (p<0.05).
23
 Use of EGCG prevented reductions 138 
in body weight and restored spleen and thymus induced hypotrophy compared to the chronic fatigue 139 
rat group (p<0.05), with significantly greater prevention of body weight reduction and spleen 140 
hypertrophy restoration using 100mg/kg dose verse 50mg/kg dose (p<0.05).
23
 In an elevated plus 141 
maze learning task administration of EGCG decreased initial transfer latency compared to the 142 
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chronic fatigued group (p= <0.05).
23
 Use of an oral dose of EGCG also showed favourable 143 
statistically significant changes in measures of oxidative and nitrosative stress and pro-144 
inflammatory cytokine levels, factors which may contribute to fatigue development.
22-24
  145 
For the polyphenol naringin, differing oral doses were administered to mice treated with 146 
lipopolysaccharide (LPS) or brucella abortus (BA) antigen which induced immunological fatigue.
24
 147 
Naringin use showed a statistically significant and dose-dependent decrease in the duration of 148 
immobility in immunologically induced fatigued mice (p= <0.05) and a significant increase in mean 149 
tail withdrawal latency compared to BA or LPS injected mice (p= <0.05).
24
 A statistically 150 
significant dose dependant increase in reduced glutathione levels was also seen through naringin 151 
administration compared to BA or LPS injected mice (p= <0.05).
24
 Again, as seen with use of the 152 
other polyphenols, statistically significant favourable changes in measures of oxidative and 153 
nitrosative stress and a pro-inflammatory cytokine were highlighted.
24
 154 
 155 
Dietary interventions and CFS symptom alleviation 156 
Only one eligible study assessed a dietary intervention with reference to CFS symptoms 157 
alleviation.
4
 The experiment applied a twenty-four week intervention of a low sugar low yeast diet 158 
(LSLY), with intention to treat analysis showing no statistically significant difference for the 159 
intervention and guideline based healthy eating control between the primary outcome measures.
4
 160 
Compliance was poor, compliant analysis was performed only on baseline characteristics 161 
comparing those who completed their role in the experiment and those that did not.
4
 162 
 163 
Dietary intake and poor vitamin or mineral status and CFS 164 
Three studies examined dietary intake and associated correlations to CFS.
25-28
 Differing dietary 165 
intake patterns were highlighted through a descriptive observational study design, with findings of 166 
dairy and grain avoidance most prominent in the CFS cohort evaluated.
25
 These dietary restrictions 167 
in many cases were reported to be undertaken due to provision of non-evidence based information 168 
and diagnostic testing from alternative therapy practitioners.
25
 Very little correlation of abnormal 169 
biomarkers with inadequate nutritional intake in CFS patients was displayed in another descriptive 170 
observational study.
28
 The findings continued in a consistent manner highlighting through an 171 
analytical observational study 95% had poor fibre intake and 70% had unhealthy fat, fruit, and 172 
vegetable intake measured through defined cut off limits from questionnaire assessment tools.
27
 173 
Yet, lifestyle factors including overweight and unhealthy dietary intake were not significantly 174 
associated with fatigue severity or functional impairment.
27
 175 
One study considered the vitamin status and direct association of CFS symptoms alleviation. The 176 
analytical observational study examined mean serum 25 OH vitamin D levels. Levels were 177 
highlighted to be moderately to severely suboptimal in CFS participants at 60.1% for those not 178 
 6 
taking supplements. This finding was statistically significantly lower over winter/spring (p= <0.04) 179 
and summer/autumn (p= <0.003) compared to the general population control study arm,
26
 yet no 180 
observed relationship for alleviation of symptoms of CFS was seen.
26
 181 
 182 
Supplements and CFS symptom alleviation 183 
Three experimental studies examined use of single nutrient supplements.
33-35
 Following on from the 184 
aforementioned serum 25 OH vitamin D analysis, an experimental trial investigated the use of an 185 
oral vitamin D3 supplement.
35
 The measured outcomes from this trial pertinent to the review 186 
highlighted no statistically significant improvement for both fatigue or for the selected markers of 187 
inflammatory and oxidative stress.
35
  188 
Secondly, probiotic supplementation was examined finding no significant change.
33
 Six of fifteen 189 
participants in this study did report subjective improvement after the trial and statistically 190 
significant improvement was seen for the neurocognitive function measures (p= 0.04), yet no 191 
significant changes in aerobic intestinal microflora were found.
33
 192 
Another study observed supplementation using D-ribose.
34
 Significant improvement for energy 193 
levels between pre and post enrolment in the compliant analysis was seen (p<0.0001, CI; 1.1-2.2) 194 
and 65.7% of participants indicated improvement in regard to their overall subjective feelings.
34
  195 
Regarding the experimental studies examining polynutrient supplements, one vitamin and mineral 196 
supplement study highlighted statistically significant improvements for before and after 197 
measurements of superoxide dismutase (SOD) antioxidant enzyme activity (p≤ 0.005).
31
 Aspects of 198 
fatigue measures showed statistically significant improvement in fatigue itself (p= 0.0009), sleep 199 
disorder (p= 0.008), autonomic nervous system symptoms (p= 0.018), headaches (p= 0.0001), and 200 
subjective feelings surrounding infection (p= 0.0002).
31
 Some aspects of quality of life measures 201 
were also statistically significant including total physical function (p= 0.053), physical role (p= 202 
0.031), pain (p= 0.01), mental vitality (p= 0.029) and mental health function scores (p= 0.014).
31
 203 
Yet, in another study trialing a vitamin and mineral supplement no statistically significant 204 
relationship was seen.
32
 Furthermore, another study also experimentally addressed polynutrient 205 
supplementation seeing no statistically significant results with fatigue, disability and symptoms 206 
assessed through the primary measured outcomes.
30
 207 
Lastly, practices of mixed self-applied supplementation were observed in an analytical 208 
observational study.
29
 Minimal changes in fatigue were shown over the follow up period in 209 
response to a range of different self-applied therapies, including nutritional therapies.
29
 A small 210 
number of the total cohort found a nutritional therapy useful, with ginseng found to be most helpful 211 
(56%) within users.
29
 Measured outcomes compared to effect of different nutritional therapies 212 
revealing inconsistent results. Magnesium (no specified dose) at six months was statistically 213 
significant with improvement in fatigue (p= 0.002), yet at two years showed no significant 214 
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relationship.
29
 Calcium (no specified dose) was introduced by participants at six months to two 215 
years and showed statistically significant improvement in fatigue (p= 0.01), yet was based on five 216 
participants.
29
 217 
 218 
Fatty acids and CFS symptom alleviation 219 
Three eligible studies regarding fatty acids were considered in relation to CFS symptoms.
36-38
 In an 220 
analytical observational study a statistically significant reduction was shown in the CFS cohort for 221 
the omega three (n-3) to omega six (n-6) polyunsaturated fatty acid (PUFA) ratio (p=  0.0003) and 222 
eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (p= 0.02).
36
 A statistically significant 223 
positive relationship was also observed between n-3 to n-6 PUFA ratio and serum zinc (p= 0.009), 224 
an indicator of the inflammatory response.
36
 A statistically significant relationship between lowered 225 
n-3 PUFA and the expression of CD69 on activated T cells (p= <0.05) was seen.
36
 There was also a 226 
statistically significant positive relationship between the severity of CFS symptoms and certain n-227 
6,PUFA, n-9 PUFA, oleic and palmitic acid (p= <0.05) and a statistically significant negative 228 
relationship between n-3 to n-6 ratio and severity of CFS symptoms (p= 0.027).
36
  229 
An essential fatty acid (EFA) supplement rich in EPA was individually examined in a case study.
37
 230 
Depression scores dropped from 27 at baseline to 3 at 16 weeks and the lateral ventricular volume 231 
of the brain had decreased at 16 weeks for the CFS participant.
37
 Yet, another experimental trial of 232 
an EFA supplement verse a placebo supplement of sunflower oil showed no statistically significant 233 
difference in the RBC membrane fatty acid profile and symptoms scores between the intervention 234 
and control group.
38
  235 
 236 
Tryptophan and glutamine amino acids and CFS 237 
The amino acid tryptophan (Trp) and its potential role in CFS symptoms expression was examined 238 
in two studies.
39, 40
 Within one, the selected CFS cohort displayed a significantly higher mean free 239 
(48%, p= 0.0000) and total Trp (19%, p= 0.0016).
39
 Serum free Trp to competing amino acids 240 
(CAA) ratio was significantly higher (43% p= 0.0000) in the CFS cohort and the serum total Trp to 241 
CAA ratio was only significantly higher when co-varied with age and gender (p= 0.0562).
39
 Non-242 
esterified fatty acid (NEFA) levels were significantly higher in the CFS cohort (p= 0.0192), as was 243 
serum glucose (p= 0.0058) and a slightly higher albumin concentration was also seen in the CFS 244 
cohort (p= 0.0016).
39
 Total CAA concentration though was not significantly different between the 245 
healthy control cohort and CFS cohort.
39
 Within CFS participants if suggested serotonin parameters 246 
are applied there was a significant division in this cohort between those with high or normal 247 
serotonin status shown in free Trp (p= 0.0002) and total Trp to CAA ratio (p= 0.0195) and free Trp 248 
to CAA ratio (p= 0.0000).
39
  249 
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Within the second study, the amino acid blood sample findings were related to the research 250 
question.
40
 These findings highlighted baseline free Trp was significantly lower in the CFS cohort 251 
(p= 0.033) with no difference seen in neutral amino acid (NAA) concentration between the two 252 
groups.
40
 Although lowered, there was no significant difference between groups for serum free Trp 253 
to NAA ratio and there was no difference for total Trp between the groups.
40
 254 
For the amino acid glutamine, the one experimental study revealed baseline measurements of 255 
participants with CFS had significantly lower mean plasma (p= <0.001) and muscle (p= 0.027) 256 
glutamine concentrations.
41
 Post trial outcomes for those with CFS in the intervention group 257 
receiving a glutamine supplement highlighted there was a significant increase in plasma and muscle 258 
glutamine concentration (p= <0.05).
41
 Those with CFS in the placebo group saw no significant 259 
increase in plasma or muscle glutamine concentrations (p= >0.05).
41
 Although supplementation 260 
increased stores of glutamine for CFS participants, those with CFS in the intervention group 261 
showed no statistically significant change in their five category questionnaire scores assessing 262 
symptoms, whereas CFS participants in the placebo group showed a significant decrease in the two 263 
categories of emotionality (p= 0.02) and sleep problems (p= 0.02).
41
 Grouping CFS participants to 264 
show clinical improvement or no clinical improvement displayed both the intervention and control 265 
groups in each category.
41
 266 
The CFS participants in the group which showed no clinical improvement did display significant 267 
increases in mean plasma glutamine concentration (p= 0.013) post trial as well as increases in their 268 
T-cell counts (p= 0.010), T-helper cells (p= 0.002) and a decrease in natural killer cell counts (p= 269 
0.019) and activated T-cells (p= 0.015).
41
 These outcomes oppose the reported baseline measures in 270 
the initial assessment, yet were not seen in the group which displayed clinical improvement. 271 
 272 
Phosphate diabetes and consideration of differential diagnosis to CFS 273 
Mean serum phosphate concentration was outlined to be significantly lower in the CFS cohort (p= 274 
0.01) but still within reference range in the single included analytical observational study.
42
 275 
Fourteen percent of participants in the CFS cohort fulfilled diagnostic criteria for phosphate 276 
diabetes (PD), yet did not show a significant difference in symptoms when compared to those with 277 
CFS without a PD diagnosis. No statistically significant difference was seen between the 278 
intervention and control for mean overall values such as phosphate clearance, mean renal threshold 279 
phosphate concentration (TmPO4/GFR) and mean phosphate tubular re-absorption (PTR) rate 280 
values.
42
 281 
 282 
Discussion  283 
Within this review no definitive dietary modification was found for alleviation of the symptoms for 284 
individuals with CFS. Some promising research though has been examined. The alternative 285 
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hypothesis that dietary modifications are useful in alleviating the symptoms of CFS has not been 286 
substantiated within this review. 287 
The included animal studies set a good platform for further human studies to be conducted in these 288 
areas of interest, with some encouraging significant results highlighted through polyphenol use in 289 
mice or rats displaying induced fatigue.
22-24
 Further studies in humans should consider 290 
supplementation of these isolated polyphenol compounds, as the results highlighted are unlikely to 291 
be obtained through normal dietary intake, for example, to obtain the effects seen from naringin 292 
around 50-200 mg/kg was administered.
24
 Mean values of several fruit varieties high in naringin, 293 
including red grapefruit, blond grapefruit and sweetie fruit, showed around 50 mg/100 g of fresh 294 
weight from fruit identified, further impeded by it’s bioavailability in the food matrix.
43
 295 
Experimental LSLY dietary intervention was inconclusive. Although, bias from poor compliance 296 
must be considered when interpreting these findings, with compliance not analysed against the 297 
measured outcome scores. Other reasons for such a finding may be potentially due to lack of power 298 
masking a result.
4
 The results may have been clouded from the beginning as the studies hypothesis 299 
relied on dietary treatment of a suggested cause of CFS. Both the suggested cause and use of dietary 300 
modification for this suggested cause (LSLY diet) lacked any supporting scientific data, are 301 
controversial and to date have not been linked directly to CFS.
4
  302 
Dietary intake patterns and poor vitamin or mineral status were not found to be associated with 303 
symptoms alleviation in the observational studies reviewed.
25-28
 Some important trends were found 304 
within these studies. One study notably observed in their selected CFS cohort almost half of the 305 
dietary exclusions were made based on information from practitioners of alternative therapy or 306 
experience.
25
 Those following this advice tended to have higher vitamin supplement intake which 307 
may be detrimental as discussed by Mursu et al.
44
, who noted that vitamin and mineral supplements 308 
increased total mortality risk in a cohort of generally healthy women with a mean age of 60 years. 309 
Although this study displays a low level of evidence and had many limitations
25
, these trends 310 
regarding food avoidance and its influence on the diets of those with CFS are important to note for 311 
research and clinical practice in order to ensure the information being distributed and followed 312 
within CFS populations is correct and has a sound evidence base. Some supplementation 313 
recommendations were highlighted in light of other findings. Due to the nature of CFS with 314 
increased in-door dwelling, potential increased osteoporosis risk and significantly lower mean 315 
serum 25-OH vitamin D, vitamin D intake through the diet and supplements should be considered 316 
for general health, regardless of the study findings
26
. The risk of chronic vitamin D deficiency 317 
mimicking CFS symptoms is also noted in two studies.
26, 28
 One study continues, suggesting that an 318 
underlying pathological process may be responsible for abnormal biomarkers which showed very 319 
little correlation with inadequate nutritional intake
28
, an explanation that may also explain lifestyle 320 
factors of weight and dietary intake not significantly correlating with CFS symptoms.
27
 321 
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For the three experimental studies of single nutrient supplements varied results were seen.
33-35
 For 322 
the study considering probiotic supplementation it was not clear whether participant compliance 323 
was measured and this may have influenced the inconsistent results.
33
 In part, this result may have 324 
been seen as this trial might not have used a high enough dose or may have focused on too many 325 
different strains of bacteria at once, with Rao et al.
45
 supporting this hypothesis, highlighting 326 
positive outcomes for anxiety and intestinal microflora using a higher single strain probiotic dose. 327 
With this understanding of the included probiotic experiment, the potential relationship between the 328 
gut-brain axis and probiotic use and the gut microbiota for CFS is further reinforced and needs 329 
continued investigation, D-ribose was highlighted to have positive preliminary results although 330 
further investigation should be made as the quality rating identified a potential conflict of interest.
34
  331 
Polynutrient vitamin and mineral supplements again displayed inconsistent results across the studies 332 
included.
30-32
 Data from Brouwers et al.
30
 and Martin et al.
32
 showed no statistically significant 333 
relationship between CFS symptoms and polynutrient supplementation, respectively.
30, 32
 One of 334 
these experimental studies
32
 did show better non significant scores than those not using the vitamin 335 
and mineral supplement. Regardless, these studies do not support general prescription of 336 
polynutrient supplements to individuals with CFS. Maric et al.
31
 highlighted a number of 337 
statistically significant results, yet the overall inconsistent results were displayed across the 338 
measured outcomes. It was suggested that potentially the vitamin and mineral supplement was 339 
working on an inflammatory level, with symptoms related to inflammation significantly improving 340 
alongside superoxide dismutase (SOD) activity.
31
 The change in SOD activity could possibly imply 341 
an effect of lowering inflammatory cytokine concentration, overall suggesting decreased levels of 342 
oxidative stress could perhaps influence CFS symptoms.
31
 This suggestion is complemented by 343 
Morris et al.
46
 in sighting that low grade inflammation from heightened pro-inflammatory cytokines 344 
are characteristic in those with CFS and that antioxidant use may be helpful. These 345 
antioxidant/cytokine hypotheses align with the results seen in the animal models of polyphenols and 346 
their positive changes to induced fatigue and corresponding cytokine measured outcomes.
22-24
 347 
Mixed self-applied supplementation gave inconsistent results. Within the included analytical 348 
observational study a list of different therapies used over the study duration was cited by noting the 349 
most commonly used therapies amongst participants.
29
 This allows for many other potential 350 
treatments to also have been in use concurrently to the listed therapies and dramatically decreases 351 
the accuracy of the results.
29
  352 
Studies examining the role of fatty acids and CFS highlighted some positive outcomes, yet overall 353 
inconsistent results were seen.
36-38
 One  experimental study returned no significant results, although, 354 
the supplements used may have acted as a confounder to these results.
38
 An EFA supplement 355 
containing a range of fatty acids, both n-3 and n-6 PUFA was used although the control supplement 356 
did not contain EPA and DHA. Mixing n-3 and n-6 PUFA could have negatively contaminated the 357 
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results
38
 as highlighted by Maes et al.
36
 who made observations regarding plasma free fatty acids. 358 
Although, Puri et al.
37
 did see significant results within their case study from a mixed EFA 359 
supplement (predominately n-3 PUFA), the previous hypothesis that n-6 PUFA may negatively 360 
impact results should still be taken into consideration for further research work. The positive 361 
outcomes seen from supplementation with predominately omega three fatty acids and observations 362 
in plasma free fatty acids could indicate the anti-inflammatory role of omega three fatty acids 363 
imparting positive effects for inflammatory response in CFS as well as some symptoms reduction.
36
  364 
Findings again were inconsistent for those studies examining the role of tryptophan and glutamine 365 
amino acids and CFS.
39-41
 CFS participants displayed a significantly higher serum free Trp to CAA 366 
ratio with increased Trp available to the brain, highlighting an excess of central serotonin by one 367 
analytic observational study.
39
 Although, this was only due to higher serum free Trp as CAA 368 
concentration was not different between the two groups. Unfortunately some of the CFS cohort had 369 
not fasted and this confounder significantly increased the concentration level of serum free Trp, 370 
hence affecting the validity of the serum free Trp to CAA ratio. In light of this result, conflicting 371 
findings are understood from another included analytical observational study.
40
 This data highlights 372 
potential implications for the management of CFS, proposing that CFS patients may be divided into 373 
sub-groups of those with normal or those with high serotonin status.
39
 It must be noted that within 374 
Vassallo et al.
40
 observational study, the amino acid level investigation and results observed were 375 
reviewed, yet the other sub sectors of this study were not relevant to the research question having 376 
largely a neuroendocrine focus. 377 
Glutamine amino acids findings showed experimentally that a CFS cohort at baseline displayed 378 
significantly lower mean plasma and muscle glutamine concentration, yet it is stated this is likely 379 
because of four participants low values.
41
 Post trial outcomes show those with CFS in the 380 
intervention group saw a significant increase in plasma and muscle glutamine concentration as 381 
compared to CFS participants in the placebo group who saw no significant increases. This indicates 382 
the effectiveness of glutamine supplementation in increasing the bodies supply of the amino acid.  383 
Inconsistent results though were highlighted with use of categorisation of CFS participants into 384 
clinical improvement or no clinical improvement groupings, with a statistically significant increase 385 
for those who did not show clinical improvement post trial in mean plasma glutamine 386 
concentration. It is proposed that a rise in only plasma glutamine for this group indicates an issue of 387 
glutamine regulation rather than decreased availability of glutamine in those with CFS. 388 
Overall it can be stated glutamine supplementation increased body supplies of glutamine but 389 
demonstrated inconsistent effects on reported symptoms or clinical improvement.  390 
Phosphate diabetes (PD) CFS cohort findings were contradictory and although still within reference 391 
range, the CFS group did display a significantly lower mean serum phosphate concentration in the 392 
included analytical observational study.
42
 Fourteen percent of the CFS cohort did meet the PD 393 
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diagnostic criteria, whereas no one in the healthy control group met the diagnostic criteria. Further 394 
studies therefore should rule out the need for consideration of PD upon clinical presentation of CFS 395 
symptoms to ensure the diagnosis and management are correct.  396 
Restricted primary research regarding this topic is a limitation of this review, not only is the data of 397 
lower quality and evidence level, the extent of research currently is narrow.
5, 13-15
 Weaknesses exist 398 
within the body of evidence and add to the complexity of this topic. Weaknesses include a variety 399 
of differing case definitions and diagnostic criteria for CFS, with the Institute of Medicine 400 
redefining CFS highlighting this weakness and aiming to address it.
1, 3, 10
 Furthermore, a vast 401 
number of assessment tools and measures, displaying varying levels of validity are in use for CFS.
1, 402 
3
 Relevant insights of study limitations are provided in this review, yet the aforementioned 403 
weaknesses meant that assessment of bias had to be carefully considered. Rather than a uniform 404 
assessment of bias be made across the included studies, an overview of individual assessments of 405 
limitations, validity and bias was made, provided in Supplementary File 2 available online. 406 
Limitations of relatively small sample sizes across much of the included primary research existed, 407 
with none of the included studies using an Australian cohort. Further research may benefit from 408 
including larger numbers and potentially multi country study designs to ensure greater 409 
generalisability to the CFS population.
3
 As commonly evident in systematic reviews some level of 410 
publication bias may be present as only published primary research met the strict inclusion criteria.  411 
Not only is there a need for stronger study design and larger sample size use, but also a need for 412 
research to assess varying whole diet interventions being applied, as currently from included data in 413 
this review only one primary research paper included a specific dietary intervention trial
4
 with more 414 
emphasis in the current body of evidence on supplementation or single nutritive factors.  415 
 416 
Conclusion 417 
Overall the evidence displayed inconsistent results across data themes which emerged, with only 418 
limited dietary modifications shown to be useful in alleviating symptoms of CFS. The evidence-419 
base included many studies of lower levels of evidence according to the National Health and 420 
Medical Research Council
18
 421 
At present, effective dietary changes have not yet been substantiated within this review, including 422 
effective communication and implementation of dietary interventions tailored to meet the needs of 423 
the CFS population.
4
 Individualized clinical recommendations still need to focus on evidence-based 424 
advice and dietary counselling, alongside general promotion of healthy eating habits across all 425 
medically tolerable food groups in order to also reduce other chronic disease risks and avoid 426 
development of deficiencies.
25, 47
 427 
Overall further research surrounding the research question and data themes presented in this review 428 
is needed. It is hoped that further research will focus on strengthening the level of evidence 429 
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contributing to future research in this area in order to clarify and consolidate recommendations as 430 
well as ensure the distribution of accurate and useful information at a population level. 431 
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Figure 1 Flow diagram of database searches 
Search One: Scopus 
Total Records Retrieved: 142 
Example Search Strategy: “chronic 
fatigue syndrome” OR “CFS” AND 
“diet*” AND “supplementation*” 
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Search Two: Cinahl Plus 
with Full Text 
Total Records Retrieved: 
243 
 
Duplicates removed: 5 
Records screened: 435 Records excluded: 387 
Full-text articles assessed for 
eligibility: 48 
Full-text articles excluded: 
21 articles did not meet inclusion criteria components, were not a primary study 
or were reviewing disproved treatment strategies i.e. homeopathy 
(21)
 
Total number of studies included: 27 
Search Three: Web of 
Science 
Total Records Retrieved: 31 
 
Search Four: PsycINFO 
Total Records Retrieved: 
19 
 
Total number of studies included: 22 
 
Supporting Information: Summary Table of Included Primary Research Papers for:  
“Role of Dietary Modification in Alleviating Chronic Fatigue Syndrome Symptoms: A Systematic Review” 
 
 
Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
Animal studies and polyphenols  
Kuo et al. 
(2009)
22 
- Animal study 
(N/A) 
- N/A 
Not 
manipulated 
(n=8, rats) 
 
Four groups 
(n=8)chronically 
fatigued rats 
through food 
intake restrictions 
and forced 
swimming. Some 
mice received 
treatment with 
astragalus 
membranaceus 
flavonoids (AMF) 
- 6 weeks 
- n=40 Sprague 
Dawley rats 
 
- Endurance by forced 
swimming  
- Atrophied spleen as 
measured through 
decrease in spleen/body 
weight ratio 
- Spleen cell proliferation 
- Cytokine production 
- AMF use (100mg/kg body weight) 
significantly increased endurance  
(p<0.05) compared to rats without AMF  
- Spleen/ body weight ratio not 
significantly increased with 
supplementation 
- Spleen cell proliferation significantly 
increased with supplementation (p<0.05) 
- Abnormal cytokine production levels 
regulated with supplementation (p<0.05) 
Not comparable to 
human evidence, yet  
provides a platform for 
further studies. 
Not applicable or 
generalisable to 
the CFS 
population.  
Sachdeva 
et al. 
(2011)
23 
- Animal study 
(N/A) 
- N/A 
Not 
manipulated 
(5-6 rats) 
Three intervention 
groups (n=5-6) 
One group subject 
to weight loaded 
forced swimming. 
Two other groups 
also received 
epigallocatechin 
gallate (EGCG) 
polyphenol. 
- 28 days 
- ~n=22 adult male 
Wistar rats 
- Endurance by forced 
swimming 
- Cognitive behaviour 
using elevated plus 
maze learning task  
- Grip strength using 
rota rod test 
- Locomotor activity 
using atophotometer 
and hyperalgesia 
- Brain homogenate 
oxidative stress, 
nitrosative stress, blood 
tumour necrosis factor-a 
(TNF-a) glutathione, 
superoxide dismutase, 
-  EGCG administration significantly 
increased endurance capacity and 
decreased fatigue levels (p=<0.05) 
- Greater endurance and decreased post 
fatigue levels displayed with the 
administration of 100mg/kg (p=<0.05) 
- Prevented reductions in body weight 
and restored spleen and thymus induced 
hypotrophy (p=<0.05),  
- Significantly greater prevention of body 
weight reduction and spleen hypertrophy 
restoration using100mg/kg (p=<0.05). 
- Decreased locomotive scores and 
increased time for the rota rod and 
hyperalgesia tests (p=<0.05)  
- Elevated plus maze learning task 
Not comparable to 
human evidence, yet 
provides a platform for 
further studies. 
Not applicable or 
generalisable to 
the CFS 
population.  
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
catalase activity. showed decreased initial transfer latency 
(p=<0.05) 
- Statistically significant changes in 
oxidative and nitrosative measures such 
as decreases in MDA, nitrite, and serum 
TNF-a levels and increased reduced 
glutathione, superoxide dismustase and 
catalase activity (p=<0.05) 
- Further decreases for MDA, nitrite, and 
serum TNF-a levels and increases for 
reduced glutathione, superoxide 
dismustase and catalase activity for the 
100mg/kg dose (p=<0.05) 
Vij et al. 
(2009)
24 
- Animal study 
(N/A) 
- N/A 
Injected with 
carboxy-
methyl 
cellulose (drug 
transport 
substance) 
and 
lipopolysaccha
ride (LPS) or 
brucella 
abortus (BA) 
antigen to 
induce 
immunological 
fatigue  
Naringin (natural 
polyphenol) 
administered orally  
at differing doses 
- 19 days  
- ~n=32 Albino Laca 
Mice  
- Immobility time 
- Mean tail withdrawal 
latency 
- Nano moles of MDA 
- Micro moles of GSH 
- Nitrite levels  
- Serum tumor necrosis 
factor-alpha (TNF-a) 
- Significant and dose-dependent 
decrease in the duration of immobility 
(p=<0.05) 
- Significant increase in mean tail 
withdrawal latency (p=<0.05) 
- A significant dose dependant increase 
in reduced glutathione levels (p=<0.05)  
- Oxidative and nitrosative stress 
measures such as MDA measures, brain 
nitrite levels and serum TNF-a were 
statistically significantly reduced 
(p=<0.05) 
- Not comparable to 
human evidence, yet 
does provide a platform 
for further studies 
- To obtain these effects 
around 50-200mg/kg 
naringin was 
administered.  Mean 
values of several fruit 
varieties high in 
naringin showed around 
50mg/100g of fresh 
weight.
42
 The levels 
tested may not be 
obtainable through diet 
alone. 
Not applicable or 
generalisable to 
the CFS 
population. 
Dietary interventions and CFS symptom alleviation 
Hobday et - Randomised Healthy eating Low sugar, low - 24 weeks - Chalder Fatigue Scale -Intention to treat analysis showed no - The suggested cause - Applicable to 
 3 
Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
al. (2008)
4 
controlled trial 
(level II) 
- Positive 
* ‘experimental 
study’ 
based on 
British 
Department of 
Health 
Guidelines  
yeast diet (LSLY)  - n=52 participants 
diagnosed with CFS 
(9 males and 43 
females).  
  
self report questionnaire 
for fatigue,  
- Quality of life (QoL) 
using medical outcomes 
survey short form-36 
(MOS SF-36).  
- Hospital anxiety and 
depression score 
(HADS) to assess mood.  
statistically significant difference between 
the primary outcome measures. 
 
and use of dietary 
modification for this 
study lack scientific 
evidence and are 
controversial  
-Underpowered 
-Poor compliance, 
compliant analysis on 
baseline characteristics.  
the CFS 
population, yet 
weighted toward 
the female CFS 
population  
- Participants 
recruited from 
within London 
where factors 
such as sun 
exposure are 
widely different . 
Dietary intake and poor vitamin or mineral status and CFS 
Trabal et al. 
(2012)
25 
- Cross-sectional 
pilot study (level 
IV) 
- Negative 
* ‘descriptive 
observational 
study’ 
No control 
group 
 
No intervention 
applied 
 
- Study duration N/A 
- n=28 female 
participants 
diagnosed with CFS. 
 
- Food frequency 
questionnaires (FFQ) 
and three day food 
records were collected 
and analysed for dietary 
habits and food 
restrictions  
Patterns of dairy and grain avoidance 
were described as most prominent in the 
study cohort 
- Other disease states 
were noted as 
confounders, but not 
adjusted for  
- Small study sample 
size  
 
- Applicable only 
to the female 
CFS population  
- Participants 
were from 
Barcelona, 
Spain where 
access to health 
care may vary to 
other countries.  
Jenkins and 
Rayman 
(2005)
 28 
- Case series 
(level IV) 
- Negative 
* ‘descriptive 
observational 
study’ 
No control 
group  
Participants with 
CFS displaying 
low values for 
minerals and B 
vitamins.  
- n=51 participants 
with CFS (9 males, 
42 females) 
- 4 day diet diary 
- Routine blood sample 
- Participants clinical 
evaluation using Chalder 
Fatigue Scale, the 
General Health 
Questionnaire (GHQ-
12), HADS, the Work 
Low intakes of vitamin D and E, calcium 
selenium, iodine when compared to UK 
reference nutrient intakes.  
- Abnormal biomarkers showed very little 
correlation with inadequate nutritional 
intake.  
- Time lapse between 
initial blood work and 
undertaking of the 
dietary assessment 
- The use of a food 
diary <7 days 
compromised some 
accuracy and imposed 
- Predominately 
Caucasian, 
making it less 
applicability to 
CFS population 
as a whole. 
Weighted toward 
the females 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
and Social Adjustment 
Scale and EQ-5D Health 
Questionnaire. 
bias to the participant,  - As the 
comparisons 
were made to 
the UK 
reference 
nutrient intakes 
and set in the 
setting must be 
considered  
Goedendor
p et al. 
(2009)
27 
- Case-control  
study (level III-3) 
- Neutral 
* ‘descriptive 
observational 
study’ 
 
Dutch 
population 
collected by 
Statistics 
Netherlands 
Questionnaire 
data from 247 
CFS participants  
- No duration is 
given for the 
collection of data  
- 247 participants 
with CFS; 70 male, 
177 female 
- A lifestyle 
questionnaire to 
measure smoking and 
alcohol use 
- Eating habits through 
the fat test,  
- Fuit and vegetable test 
and the fibre test 
- Body mass index (BMI) 
- Fatigue severity using 
the CIS-fatigue scale 
- Functional impairment 
using the SIP-8 scale 
- Significantly less participants in the CFS 
cohort were overweight (18-45 years) 
(p=<0.01), almost one-third CFS cohort 
had an unhealthy BMI 
- Through the fat, fruit and vegetable and 
fibre test the CFS cohort showed 95% 
had poor fibre intake and unhealthy fat 
- Fruit, and vegetable intake was 
observed in 70% of the CFS cohort  
- Lifestyle factors were not significantly 
associated with fatigue severity or 
functional impairment 
- CFS diagnostic criteria 
only allows for BMI of 
18.5-40 year olds. BMI 
only assessed in n=81 
of the CFS cohort.  
- Excess alcohol 
consumption an 
exclusion criteria for 
CFS, may also present 
as skewed results 
- This study is 
applicable to the 
CFS population  
- This study was 
conducted within 
a cohort of 
Dutch 
participants 
Berkovitz et 
al. (2009)
26 
- Retrospective  
survey (level III-3) 
- Negative 
* ‘descriptive 
observational 
study’ 
 
- A single arm 
study of 
patients with a 
variety of 
chronic 
diseases used 
as control for 
serum 25OHD 
vitamin D 
- Single study arm 
consisted of 
participants with 
CFS  
- CFS comparison 
study arm 2 years of 
laboratory data on 
serum 25OH vitamin 
D and case notes, 
n=324 participants. - 
CFS comparison 
study arm n=16 
males and n=84 
- Serum 25 OH vitamin 
D levels  
- Severity of fatigue 
assessed from case 
notes using the Myalgic 
Encephalomyelitis 
Disability Score (MEDS) 
and the Chalder Fatigue 
Scale 
Mean serum 25 OH vitamin D levels 
were moderately to severely suboptimal 
in CFS participant at 60.1% for those not 
taking supplements, statistically 
significantly lower over winter/spring 
(p=<0.04) and summer/autumn (p=< 
0.003)  
- No relationship between serum 25-OH 
vitamin D and alleviation of symptoms of 
Case notes were used 
to assess fatigue and 
may not have been 
concurrent to when the 
serum 25 OH vitamin D 
sample was taken 
 
- The sample 
was 95% 
Caucasian, 
making it less 
applicability to 
the CFS 
population as a 
whole.  
- Weighted 
 5 
Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
comparison 
 
females 
(comparable to the 
control group). 
CFS toward females 
- The setting is 
in Britain where 
factors such as 
sun exposure 
are widely 
different  
Single nutrient supplements 
Witham et 
al. (2015)
35
 
- Randomised 
controlled trial 
(level II) 
- Neutral 
* ‘experimental 
study’ 
Half of the 
study 
population 
acted as a 
control 
receiving a 
parallel 
placebo  
100,000 units of 
oral vitamin D3 or 
matching mygliol 
oil placebo  
- 6 months  
- n=50 participants 
diagnosed with CFS; 
(12 males and 38 
females).  
 
-Aarterial stiffness 
-Fatigue using the Piper 
Fatigue Scale –  
- Markers of 
inflammation and 
oxidative stress 
interleukin- 6, TNF-a, c-
reactive protein, 
derivatives of reactive 
oxygen metabolites 
- Flow-mediated 
dilatation of the brachial 
artery, blood pressure, 
cholesterol and insulin 
resistance 
Results pertinent to this review 
highlighted no statistically significant 
effects in any aspects of the Piper 
Fatigue Scale. 
No statistically significant changes w for 
all metabolic, inflammatory and oxidative 
stress outcome measures. 
- 
-Funding from ME 
research UKthough the 
funder had no role in 
the undertaking the trial 
- Not fully 
applicable to the 
CFS population, 
weighted toward 
the 
predominately 
Caucasian, 
female adult 
CFS population 
-Aa Scottish 
cohort and 
factors such as 
sun exposure 
are widely 
different  
 
Sullivan et 
al. (2009)
33
 
- Case series 
study with pre and 
post test outcomes 
(level IV) 
- Neutral 
* ‘experimental 
study’ 
No control 
group  
Probiotic 
supplement 
(Cultura Dofilus 
Natural Yoghurt) 
- 10 weeks (4 weeks 
of intervention) 
- 15 participants with 
CFS; (5 male, 10 
females). 
 
- Symptom intensity 
including neurocognitive 
symptoms using the 
Visual Analogue Scales 
(VAS)  
- Physical activity and 
general health status 
- A statistically significant improvement 
for VAS neurocognitive symptoms 
(p=0.04) 
- No significant change was seen in the 
SF-12 Health Survey measures 
- No significant change in aerobic 
intestinal microflora was found 
- Sstudyparticipants 
acted as their own 
control, though they did 
not undertake a placebo 
treatment with wash out 
period  
-  The study was 
applicable to the 
general CFS 
population 
-  
This study was 
conducted within 
 6 
Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
 using SF-12 Health  
- Stool samples 
a cohort from 
Sweden 
Teitelbaum 
et al. 
(2006)
34 
- Case series pilot 
study with pre and 
post test outcomes 
(level IV) 
- Negative 
* ‘experimental 
study’ 
 
No control Supplement of 5g 
D-ribose 3x/day 
- 17 to 35 days 
- n=36 participants 
diagnosed FMS 
and/or CFS (8 
males,28 females). 
 
- Pre and post enrolment 
discrete visual analogue 
scale (DVAS) 
questionnaire describing 
energy levels, sleep 
patterns, mental clarity, 
pain threshold and state 
of well-being  
- Post enrolment 
subjective feelings 
- Statistically significant improvement for 
energy levels (p=<0.0001, CI; 1.1-2.2, all 
other areas spanning 1 for the 95% 
confidence intervals [CI])   
- 65.7% experienced some level of 
improvement in regard to their overall 
subjective feelings.  
- Intention to treat analysis was not 
performed  
- CFS participants saw improvement in 
pre and post DVAS scores for all areas, 
with no reported p value or 95% CI 
- Gender was 
associated in some 
areas of the DVAS 
- Study sample 
mainlyfemales  
- Two of the three 
researchers worked for 
the company producing 
the D-ribose-  may have 
affected the 
interpretation of the 
results 
- Relatively small study 
sample size 
- Proper analysis 
was not given to 
CFS patients 
alone to display 
a significant 
result. 
- Participants 
were from the 
Annapolis 
region, USA 
where access to 
health care may 
vary from other 
areas  
Polynutrient vitamin and mineral supplements 
Maric et al. 
(2014)
31 
- Case series 
study with pre and 
post test outcomes 
(level IV) 
- Neutral 
* ‘experimental 
study’ 
No control 
group  
Vitamin and 
mineral 
supplement  
- 2 months 
- n=38 participants 
with CFS (all 
female). 
. 
- Before and after 
superoxide dismutase 
(SOD),  Fibro Fatigue 
Scale (FFS) for 
symptom severity and 
the Quality of Life Short 
Form-36 (QOL SF-36) 
for physical, 
psychological and social 
functioning were 
completed 
- Statistically significant improvement in 
SOD antioxidant enzyme activity 
(p=<0.005) (decreased oxidative stress 
showing decreased SOD) 
- FFS scores showed improvement in 
fatigue (p=0.0009), sleep disorder 
(p=0.008), autonomic nervous system 
symptoms (p=0.018), headaches 
(p=0.0001), and subjective feelings 
surrounding infection (p=0.0002). 
- QOL SF-36 showed statistically 
significant total physical function 
(p=0.053), physical role (p=0.031), pain 
(p=0.01) and mental vitality (p=0.029) 
- The small sample size 
may have impacted the 
ability to find further 
significant results  
- Applicable only 
to the female 
CFS population  
- Conducted 
within a cohort 
from Sweden 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
and mental health (p=0.014) function 
scores 
Martin et al. 
(1994)
32 
- Placebo 
controlled, double 
blind, cross over 
study (level II)  
- Neutral 
* ‘experimental 
study’ 
Placebo 
supplement  
Vitamin and 
mineral 
supplement  
- 6 months  
- n=42 participants 
with CFS  
General Health 
Questionnaire (GHQ) for 
physical symptoms, 
Physical Questionnaire 
(PQ) scores 
The data analysis showed no statistically 
significant relationship between CFS 
measured outcomes and the vitamin and 
mineral supplement  
- Nutritional status was 
not assessed prior to 
the study 
commencement to 
establish possible 
nutrient deficiency 
- No clear exclusion 
criteria 
 
- Applicability to 
the CFS 
population is 
likely to be high 
including 
participants with 
a sum score of 
measuring 
outcomes of 12 
or over.  
-  
Conducted 
within a cohort 
from Scotland 
where factors 
such as sun 
exposure are 
widely different 
to other contexts 
Brouwers et 
al. (2002)
30 
- Randomised 
control trial (level 
II) 
- Neutral 
* ‘experimental 
study’ 
Placebo 
supplement  
Polynutrient 
antioxidant 
supplement of a 
range of macro 
and micro 
nutrients 
- 10 weeks 
- n=53 participants 
with CFS (16 males, 
37 females). 
 
 
- Fatigue severity using 
the Checklist Individual 
Strength (CIS-fatigue) 
score 
- Disability through 
Sickness Impact Profile 
(SIP-8) score 
- CDC checklist to 
assess CFS symptoms. 
No statistically significant result was 
displayed between the control or 
intervention group in any of the outcomes 
measured 
- Effect on CFS 
symptoms, nutritional 
status was not 
assessed prior to the 
study commencement 
to establish if possible 
nutrient deficiency 
- The study doesn’t 
mention whether 
supplement containers 
- The 
applicability of 
the cohort to the 
CFS population 
was good yet 
weighted toward 
the female CFS 
population 
- Conducted 
within a cohort 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
: 
- Physical activity was 
measured through 
actometer 
- Daily fatigue through 
Daily Observed Fatigue 
(DOF) rating 
- individual self 
improvement rating 
were returned or if 
compliance was 
assessed 
from the 
Netherlands 
Mixed self applied supplementation 
Bentler et 
al. (2005)
29 
- Case series 
study (level IV) 
- Negative 
* ‘analytical 
observational 
study’ 
No control 
group  
No intervention, 
group 
- 2 years 
- n=159 participants 
with CFS (20 male, 
135 female) 
. 
- Fatigue intensity using 
a mix of the Rand 
Vitality Index and the 
Fatigue Severity Scale. 
- Somatic symptoms 
through non-validated 
questions  
- Depression was 
assessed using the 
Zung Self-Rating 
Depression Scale and 
the MOS SF-36 
- Minimal change in fatigue score - A 
small number of the total cohort found a 
nutritional therapy useful, of that 
proportion ginseng was found to be most 
helpful within users (out of 18 subjects, 
56% found this helpful) of the nutritional 
supplements considered appropriate for 
analysis within this review. 
- Inconsistent results where information 
was provided  
- Magnesium (no specified dose) at 6 
months was statistically significant with 
improvement in fatigue (p=0.002) - 
Calcium (no specified dose) was at 6 
months to 2 years showed statistically 
significant improvement in fatigue 
(p=0.01), yet was based on 5 participants  
Different therapy used 
over the study duration 
Treatments may have 
been in use 
concurrently to the 
listed therapies  
-   The study 
sample was 
heavily weighted 
toward the 
female. 
Caucasian CFS 
therefore not 
highly applicable 
to the general 
CFS population. 
- The study was 
performed within 
an American 
cohort  
Fatty acids and CFS symptom alleviation 
Maes et al. 
(2005)
36 
- Case-control 
study (level III-2) 
- Neutral 
N=12 normal 
control  
N=22 CFS 
participants 
- No exact duration 
mentioned; -  
- n=34 participants 
- Plasma free fatty acids, 
serum zinc, serum 
alpha-2 protein fraction. 
- CFS cohort showed a statistically 
significant reduction in the omega three 
(n-3) to omega six (n-6) polyunsaturated 
- Control participants 
health status was not 
described  
- Applicable to 
the general CFS 
population, 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
* ‘analytical 
observational 
study’ 
provided blood 
samples 
 
CD96 expression on T 
lymphocytes and T 
helper and suppressor 
cells  
- In the CFS cohort FMS 
and CFS Rating Scale to 
measure severity of 
symptoms 
fatty acid (PUFA) ratio (p=0.0003) and 
eicosapentaenoic acid (EPA) to 
arachidonic acid (AA) ratio (p=0.02)  
- Statistically significant positive 
relationship between n-3:n-6 PUFA ratio 
and serum zinc, an indicator of the 
inflammatory response (p=0.009)  
- Statistically significant relationship 
between lowered n-3 PUFA and the 
expression of CD69 on activated T cells 
(for CD3+ p=0.005, CD3+CD4+ p=0.04, 
CD3+CD8+ p=0.01)  
- Statistically significant positive 
relationship between the severity of CFS 
symptoms and certain n-6 PUFA (LA 
p=0.005, AA p=0.038) and n-9 PUFA 
(p=0.02), oleic (p=0.03) and palmitic acid 
(p=0.02) 
-  Statistically significant negative 
relationship between n-3/n-6 ratio and 
severity of CFS symptoms was seen 
(p=0.027) 
- No analysis of dietary 
intake was recorded  
although gender 
was not 
quantified 
-  
This study was 
conducted within 
a cohort from 
Belgium  
Puri et al. 
(2004)
37 
- Single case 
study (level IV) 
- Negative 
* ‘case study’ 
No control 
group 
Essential fatty acid 
supplement rich in 
eicosapentaenoic 
acid (EPA) 
- 16 weeks 
- n=1 female 
participant with 
diagnosed CFS 
- Depression outcome 
using the Montgomery 
and Asberg Depression 
Rating Scale.  
- Lateral ventricular 
brain size was assessed 
through MRI scan 
- Depression scores dropped from 27 at 
baseline to 3 at 16 weeks. 
- The lateral ventricular volume of the 
brain had decreased at 16 weeks 
Only one participant 
was included 
- Not applicable 
to the CFS 
population as 
only one 
participant was 
included  
- This study was 
conducted within 
a UK participant 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
where factors 
such as sun 
exposure are 
widely different 
to other contexts 
Warren et 
al. (1999)
38 
- Randomized 
control trial (level 
II) 
- Neutral 
* ‘experimental 
study’ 
Placebo 
supplement of 
sunflower oil  
Essential fatty acid 
(EFA) 
supplementation  
 
- 3 months 
- n=50 participants 
with CFS (21 men, 
29 females).  
 
- Physical Symptom 
(PS) Checklist adapted 
from another study 
- The Beck Depression 
Inventory (BDI) for 
assessment of 
depression  
- No statistically significant differences in 
the RBC membrane fatty acid profile and 
symptoms scores from PS and BDI 
between the intervention and control 
group were displayed 
 
- The EFA supplement 
contained a range of 
fatty acids, both n-3 and 
n-6 polyunsaturated 
fatty acids (PUFA), 
although the control 
supplement did not 
contain EPA and DHA, - 
Compliance of 
participates in the 
intervention group is not 
mentioned 
- The study was 
applicable to the 
general CFS 
population 
- This study was 
conducted within 
a cohort from 
England where 
factors such as 
sun exposure 
are widely 
different to other 
contexts 
Tryptophan and glutamine amino acids and CFS 
Badawy et 
al. (2005)
39 
- Case-control 
study (level III-2) 
- Negative 
* ‘analytical 
observational 
study’ 
42 healthy 
participants 
(26 males, 16 
females) 
N=23 participants 
with CFS 
- 2 year, 7 month 
period 
- n=65 participants, 
in the CFS cohort (9 
males, 14 females). 
In the control cohort  
- Serum free and total 
tryptophan (Trp), cortisol 
and amino acids, 
albumin, non-esterified 
fatty acids (NEFA), 
glucose and kynurenine, 
all exhibiting some role 
in Trp metabolism were 
measured 
 
- The CFS cohort had significantly higher 
mean free (48%, p=0.0000) and total 
(19%, p=0.0016) Trp 
- Serum free Trp to CAA ratio was 
significantly higher (43%, p=0.0000) in 
the CFS cohort  
- The serum total Trp to CAA ratio was 
only significantly higher when co-varied 
with age and gender (p=0.0562). 
- NEFA levels were significantly higher in 
the CFS cohort (p=0.0192), as was 
serum glucose (p=0.0058) and a slightly 
- Some of the CFS 
cohort were not fasted 
outcomes indicated 
significantly higher 
serum free Trp to CAA 
ratio only due to higher 
serum free Trp 
- This study is 
applicable to the 
CFS population  
-  
This study was 
conducted within 
a cohort from 
the United 
Kingdom where 
factors such as 
sun exposure 
are widely 
 11 
Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
higher albumin concentration was also 
seen in the CFS cohort (p= 0.0016). 
- Total CAA concentration though was 
not significantly different between the 
control and CFS groups  
 
different to other 
contexts 
Vassallo et 
al. (2001)
40 
- Case-control 
study (level III-2) 
- Neutral 
* ‘analytical 
observational 
study’ 
N=21 healthy 
participants (5 
males, 16 
female )( 
N=20 participants 
with CFS(4 males, 
16 female) 
 - A duration not 
mentioned 
- n=41 participants,. 
Relevant to the research 
question - plasma 
neutral amino acid 
concentration (NAAs) 
- plasma total and free 
Trp was measured 
- from these measures 
the ratio of free Trp to 
NAA was given 
Relevant to the research question were 
the amino acid findings: 
- baseline free Trp was significantly lower 
in the CFS cohort (p=0.033) 
- no difference was seen in NAA 
concentration between the two groups 
- although lowered there was no 
significant difference between groups for 
serum free Trp to NAA ratio 
 
- One participant who 
did not meet the criteria 
for CFS 
- This study is 
not applicable to 
the CFS 
population as 
one participant 
in the CFS 
cohort did not 
meet the criteria 
for CFS 
diagnosis 
-  
This study was 
conducted within 
a cohort from 
the United 
Kingdom where 
factors such as 
sun exposure 
are widely 
different to other 
contexts 
Rowbottom 
et al. 
(1998)
41 
 
- Randomised 
double blind case-
controlled trial 
(level II) 
Placebo 
supplement 
L-glutamine 
supplement 
(2000mg/day for 
trial duration) 
- 26 weeks 
- n=32 participants; 
- Glutamine status of 
control and intervention 
groups 
- Un-fasted blood 
- CFS group reported more frequently the 
occurrence of symptoms for all five 
categories of the questionnaire 
(p=<0.001)  
Relatively small study 
sample size  
The study 
population in this 
trial is applicable 
to the CFS 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
- Neutral 
* ‘experimental 
study’ 
16 participants 
with CFS (6 
males, 10 
females) 
sample for plasma 
glutamine levels, 
complete haematology, 
five cell differential 
leucocyte counts and 
cortisol and testosterone 
analysis.  
- Muscle glutamine 
concentration 
-  5 category 
questionnaire regarding 
symptom status  
 
- The CFS group showed significantly 
lower mean T-cell counts (p=0.002), T-
helper cell counts (p=0.018) and higher 
activated T-cells (p=0.027)  
- The CFS participants displayed 
significantly lower mean plasma 
(p=<0.001) and muscle (p=0.027) 
glutamine concentrations pre trial  
- CFS participants in the intervention 
group showed no statistically significant 
change in their five category 
questionnaire scores, whereas CFS 
participants in the placebo group showed 
a significant decrease in the two 
categories of emotionality (p=0.02) and 
sleep problems (p=0.02) 
- For those in the intervention group with 
CFS a significant increase in plasma and 
muscle glutamine concentration was 
seen (p=<0.05). - CFS participants who 
did not show clinical improvement 
showed significant increases in mean 
plasma glutamine concentration 
(p=0.013) post trial andsignificant 
increases in T-cell counts (p=0.010), T-
helper cells (p=0.002) and a decrease in 
natural killer cell counts (p=0.019) and 
activated T-cells (p=0.015).  
- CFS participants with or without clinical 
improvements post trial displayed 
significant increases in erythrocyte 
population and 
generalisability 
is dependant on 
the context 
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Reference Study design 
(Level of 
Evidence
†
) 
 
Quality
 
rating
20, #
 
Control Intervention: 
exposure and 
duration 
Duration 
 
Population: 
sample size. 
Outcome measures Results: 
effect size and statistical significance/ 
risk reduction 
Confounders External 
validity: 
applicability and 
generalisability 
counts, haemoglobin, haematocrit 
(p=<0.05) and a significant decrease in 
B-cells (p=<0.05)  
Phosphate diabetes and consideration of differential diagnosis to CFS 
De Lorenzo 
et al. 
(1998)
42 
- Case-control 
study (level III-2) 
- Neutral 
* ‘analytical 
observational 
study’  
N=37 healthy 
control 
participants  
N=87 participants 
with CFSod 
samples 
 
- No duration 
mentioned; - 
- Participants 
provided blood and 
urine samples 
- n=124 participants 
(51 males, 46 
females) 
 
- Urinary sodium, 
potassium, calcium and 
phosphate, b serum 
calcium and phosphate, 
parathyroid hormone 
and vitamin D were 
measured 
- Phosphate clearance, 
phosphate tubular re-
absorption (PTR) and 
renal threshold 
phosphate concentration 
(TmPO4/GFR) were all 
measured 
- Mean serum phosphate concentration 
was significantly lower in the CFS cohort 
(p=0.01) but within reference range 
- 14% of participants in the CFS cohort 
fulfilled diagnostic criteria for phosphate 
diabetes (PD), yet dno significant 
difference in symptoms  
 
- no statistically significant difference for 
overall mean values, such as phosphate 
clearance, mean TmPO4/GFR and mean 
PTR rate values 
Analysis of PD was 
performed among the 
cohort – no analysis of 
dietary intake to reduce 
the impact that poor 
dietary intake  
-  This study is 
applicable to the 
CFS population   
-  
Tonsidered as 
this study was 
conducted within 
a cohort from 
London where 
factors such as 
sun exposure 
are widely 
different to other 
contexts 
 
 
 
 

 
                                                        
† The evidence level of each included study was graded according to the National Health and Medical Research Council.19 
 A quality rating was assigned according to the Academy of Nutrition and Dietetics American Dietetic Association20 quality rating checklist allowing assessment of risk of bias within each included study and fostering 
systematic and objective quality ratings assignment. The checklist addresses relevance, applicability, validity and bias. 
 Study title descriptor given to the references when described within the systematic literature review itself to allow the reader quick reference and comparison of study designs 
FMS: fibromyalgia, CFS: chronic fatigue synrome 
 
 
